top of page

LAST DAY TO REGISTER for December Meeting

Advances in Microfluidics coupled to Mass Spectrometry and Biomarker Discovery

presented by Dr. Jose Castro-Perez from Merck

Starwood Four Points

Meriden, CT

5:30p-7:00p

Abstract: Recently there has been emphasis in the analysis of biomarkers peptides and bio-therapeutics in both academia and the pharmaceutical industry. Enzyme immunoassays have been in the majority of cases the first analytical choice in the pre-clinical and clinical spaces. Having said that, mass spectrometry has found a niche in this bioanalytical space for more selective bio-assays where enzyme immunoassays fail due to cross-reactivity. In this study, we will evaluate the use of a novel approach which focuses primarily on the sample introduction component of the MS system. More specifically, we will present the use of 150µm id microfluidics device packed with 1.7µm particle size for the analysis of a range of peptides and endogenous biomarkers in different biological matrices.

Speaker Bio: Jose Castro-Perez is part of the Cardiometabolic Biomarker and Translational Research Team at Merck, Kenilworth, NJ. His role is to provide analytical support to the various Cardiometabolic groups. Main areas of focus are; lipidomics, biomarker quantitation for small molecules and peptides, stable isotope tracer and flux analysis. He has a wealth of experience of more than 20 years in the field of Drug Metabolism, Metabolomics & Lipidomics. Before his post at Merck, he held a position at Waters Corp as a Senior Business Development Manager; in his role he was responsible for the introduction of the QTof technology and accurate mass back in 1996 for small molecule applications. During his role he was in charge of the development and collaborations of LC/MS applications for Metabolite Identification using Time of Flight Technology and software applications within the pharmaceutical and biotech industry. Prior to joining Waters, he worked at Huntingdon Life Sciences (CRO) as a Senior Bio-analyst where he managed Phase II and III clinical trials in regulated bio-analysis in the laboratory using LC/MS/MS and enzyme immunoassays. He has published extensively in top scientific journals with a total of 55 publications. He is a well known figure in the mass spectrometry world as he has lectured extensively on the areas of Metabolomics, biomarkers and metabolite identification at various symposia and meetings around the world. He attained his Bachelor of Science in Chemistry from King's College in London (UK) and subsequently received his Master of Science in Clinical Biochemistry and Molecular Biology from the University of Surrey (UK). Further post-graduate study concluded in obtaining his PhD at the University of Leiden (The Netherlands) in Metabolomics and Biomarker discovery.


bottom of page